479 related articles for article (PubMed ID: 28866421)
1. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
4. Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.
Dutra LA; de Almeida L; Passalacqua TG; Reis JS; Torres FA; Martinez I; Peccinini RG; Chin CM; Chegaev K; Guglielmo S; Fruttero R; Graminha MA; dos Santos JL
Antimicrob Agents Chemother; 2014 Aug; 58(8):4837-47. PubMed ID: 24913171
[TBL] [Abstract][Full Text] [Related]
5. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.
Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA
Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453
[TBL] [Abstract][Full Text] [Related]
6. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
8. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
9. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF
Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802
[TBL] [Abstract][Full Text] [Related]
11. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
13. Effects of nitro-heterocyclic derivatives against Leishmania (Leishmania) infantum promastigotes and intracellular amastigotes.
Petri e Silva SC; Palace-Berl F; Tavares LC; Soares SR; Lindoso JA
Exp Parasitol; 2016 Apr; 163():68-75. PubMed ID: 26795261
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.
de Moura TR; Santos ML; Braz JM; Santos LF; Aragão MT; de Oliveira FA; Santos PL; da Silva ÂM; de Jesus AR; de Almeida RP
Parasitol Res; 2016 Feb; 115(2):713-21. PubMed ID: 26481489
[TBL] [Abstract][Full Text] [Related]
17. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives.
Tavares J; Ouaissi A; Silva AM; Lin PK; Roy N; Cordeiro-da-Silva A
Parasitol Int; 2012 Jun; 61(2):360-3. PubMed ID: 22155672
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
19. Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Pereira IAG; Mendonça DVC; Tavares GSV; Lage DP; Ramos FF; Oliveira-da-Silva JA; Antinarelli LMR; Machado AS; Carvalho LM; Carvalho AMRS; Salustiano IV; Reis TAR; Bandeira RS; Silva AM; Martins VT; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Duarte MC; Menezes-Souza D; Coimbra ES; Leite JPV; Coelho EAF; Gonçalves DU
Parasite Immunol; 2020 Dec; 42(12):e12784. PubMed ID: 32772379
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.
Jesus JA; Fragoso TN; Yamamoto ES; Laurenti MD; Silva MS; Ferreira AF; Lago JH; Santos-Gomes G; Passero LF
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):1-11. PubMed ID: 27984757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
